Ibrutinib-venetoclax found highly active in hard-to-treat CLLJuly 22, 2019Leukemia, Myelodysplasia, TransplantationHematology
SC daratumumab deemed feasible for every multiple myeloma patientJuly 11, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersHematology
Ibrutinib tops chlorambucil against CLLJuly 10, 2019Leukemia, Myelodysplasia, TransplantationHematology
CNS-directed therapy appears more effective for synDLBCLJuly 9, 2019Lymphoma & Plasma Cell DisordersHematology
Cell count ratios appear to predict thromboembolism in lymphomaJune 25, 2019Lymphoma & Plasma Cell DisordersHematology
For tough AML, half respond to selinexor plus chemotherapyJune 25, 2019AMLLeukemia, Myelodysplasia, TransplantationHematology
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapyJune 7, 2019Leukemia, Myelodysplasia, TransplantationHematology
Daratumumab regimen shows benefit in transplant-ineligible myelomaMay 29, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersHematology
Genetic analysis identifies prognostic markers in CLLMay 28, 2019Leukemia, Myelodysplasia, TransplantationHematology
